Stock events for Accuray, Inc. (ARAY)
Accuray's stock has experienced a significant decline over the past six months. Key events impacting the stock price include Q1 Fiscal Year 2026 financial results, which reported a decrease in total net revenue and a net loss. A leadership change and transformation plan were announced in October 2025, involving organizational realignment and workforce optimization. Q2 Fiscal Year 2026 earnings reported an EPS of -$0.11, meeting analyst consensus, and quarterly revenue of $102.24 million, which was above the consensus estimate.
Demand Seasonality affecting Accuray, Inc.’s stock price
Accuray's product revenue can experience seasonal weakness, but recent declines were more severe than usual seasonal patterns. Demand for the CyberKnife system has seen growth due to the clinical trend towards shorter treatment courses.
Overview of Accuray, Inc.’s business
Accuray Incorporated specializes in radiation treatment solutions for cancer and tumors. Its core mission is to expand the potential of radiation therapy to improve lives. Major products and platforms include the CyberKnife System, Radixact System, TomoTherapy Platforms, Accuray Precision Treatment Planning and iDMS Data Management, Veterinary Oncology products, and various services.
ARAY’s Geographic footprint
Accuray is headquartered in Madison, Wisconsin, USA, with additional facilities worldwide. The company has a global presence, with its CyberKnife and TomoTherapy platforms installed in approximately 50 countries. Accuray maintains regional offices in Morges, Switzerland; Hong Kong, China; Chengdu, China; and Tokyo, Japan. Manufacturing facilities are located in both the U.S. and China.
ARAY Corporate Image Assessment
Accuray has historically received high user satisfaction ratings, particularly for its CyberKnife and TomoTherapy Systems. Strong patient awareness and branding for the CyberKnife system have been noted. However, recent financial struggles and workforce reduction could potentially affect stakeholder perception.
Ownership
Institutional investors are the primary owners of Accuray, Inc., holding a substantial majority of the company's shares. Insider ownership stands at approximately 2.26% as of July 30, 2025.
Ask Our Expert AI Analyst
Price Chart
$0.41
